Den Europæiske Union - dansk - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - radionuklidbilleddannelse - terapeutiske radioaktive lægemidler - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

immunomedics gmbh - sulesomab - osteomyelitis; radionuclide imaging - diagnostiske midler - dette lægemiddel er kun til diagnostisk brug. leukoscan er angivet til diagnostisk billeddannelse for placering og omfang af infektion/betændelse i knogler hos patienter med formodet osteomyelitis, herunder patienter med diabetiske fodsår. leukoscan har ikke været ansat til at diagnosticere osteomyelitis hos patienter med seglcelle anæmi.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pharmaxim sweden ab - bacitracin, benzylpenicillinkalium, neomycin - intramammær salve - kvæg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

padma europe gmbh - aegle marmelos frugt, pulver, gul potentil, islandsk mos, kaempferia galanga rhizoma, kryddernellike, morgenfrue blomst, myrobalan frugt, paternostertræ, frugt - tabletter

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

monrol europe s.r.l. - natriumiodid (131-i) - kapsler, hårde - 37-7400 mb

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostiske radioaktive lægemidler - dette lægemiddel er kun til diagnostisk brug. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy.  celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. hos voksne patienter, til at hjælpe med at differentiere sandsynligt, demens med lewy organer fra alzheimers sygdom.  celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

cis bio international oris ind. - natriummolybdat (99m-mo) - radionuklidgenerator

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

cis bio international oris ind. - tetrakis kobber(i) tetrafluoroborat - radiofarmaceutisk præparationssæt - 1 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklidbilleddannelse - diagnostiske radioaktive lægemidler - dette lægemiddel er kun til diagnostisk brug. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - prostatic neoplasmer, kastration-resistent - terapeutiske radioaktive lægemidler - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.